19 August 2024
Futura Medical
plc
("Futura" or the
"Company")
Notice of
Results
Futura Medical plc (AIM:
FUM), the consumer healthcare company
behind Eroxon®, that specialises in the development
and global commercialisation of innovative and clinically
proven sexual health products, will announce its unaudited
results for the six months ended 30 June 2024 on Tuesday 10
September 2024.
The Company will be hosting a
webinar for retail investors via the Investor Meet Company platform
on 10 September 2024, at 9:00am BST. The presentation is open to
all existing and potential shareholders. Questions can be submitted
pre-event via the Investor Meet Company dashboard up until 9:00am
BST the day before, or at any time during the live
presentation.
Investors can register for the
presentation via the following link:
https://www.investormeetcompany.com/futura-medical-plc/register-investor
In addition, management will be
hosting a webinar for analysts on 10 September 2024 at 11:00am BST.
If you would like to register, please contact
futura@almastrategic.com
Contacts:
|
Futura Medical plc
|
James Barder
Chief Executive Officer
Angela Hildreth
Finance Director and COO
|
investor.relations@futuramedical.com
+44 (0)1483 685 670
www.futuramedical.com
|
|
Panmure Liberum
Nominated Adviser
and Broker
|
Emma Earl, Will Goode, Mark Rogers
(Corporate Finance)
Rupert Dearden (Corporate
Broking)
|
+44 (0)20 3100 2000
|
|
|
|
|
|
Stifel Nicolaus Europe Limited
Joint Broker
|
Alan Selby
Ben Maddison
|
+44 (0)207 710 7600
|
|
|
|
|
|
Alma Strategic Communications
|
Rebecca Sanders-Hewett
Sam Modlin
Will Ellis Hancock
|
+44 (0)20 3405 0205
futura@almastrategic.com
|
|
|
|
|
Notes to Editors:
Futura Medical plc (AIM: FUM) is the
developer of innovative sexual health products, including lead
product Eroxon. Our core strength lies in our research, development
and commercialisation of topically delivered gel formulations in
sexual health products.
Eroxon, Futura's clinically proven
lead product, has been developed for the treatment of Erectile
Dysfunction ("ED"). The highly differentiated product,
which is the only topical gel treatment for ED available over the
counter and helps men get an erection in ten
minutes, addresses significant unmet needs in the ED
market.
ED impacts 1 in 5 men globally
across all adult age brackets, with approximately half of all men
over 40 experiencing ED and 25% of all new diagnoses being in men
under 40.
Futura has distribution partners in
place in a number of major consumer markets including Haleon in the
US, the largest market for ED in the world, and Cooper Consumer
Health in Europe. Eroxon has been nominated for a number of
healthcare industry awards and has won two to-date.
